Resultados de procura - Birgit Geoerger

Limitar resultados
  1. 1
    Precision medicine in pediatric oncology

    Precision medicine in pediatric oncology por Suzanne J. Forrest, Birgit Geoerger, Katherine A. Janeway

    Publicado 2017
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Metabolic activity and clinical features of primary ganglioneuromas

    Metabolic activity and clinical features of primary ganglioneuromas por Birgit Geoerger, Barbara Hero, D. Harms, Jochen Grebe, Klemens Scheidhauer, Frank Berthold

    Publicado 2001
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine

    Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine por Célia Dupain, Anne C. Harttrampf, Giorgia Urbinati, Birgit Geoerger, Liliane Massaad-Massade

    Publicado 2017
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  4. 4
    Biological stability of RNA isolated from RNAlater-treated brain tumor and neuroblastoma xenografts

    Biological stability of RNA isolated from RNAlater-treated brain tumor and neuroblastoma xenografts por Michael Grotzer, Ratnakar Patti, Birgit Geoerger, Angelika Eggert, Thomas T. Chou, Peter C. Phillips∥

    Publicado 2000
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    High Levels of Circulating VEGFR2+ Bone Marrow–Derived Progenitor Cells Correlate with Metastatic Disease in Patients with Pediatric Solid Malignancies

    High Levels of Circulating VEGFR2+ Bone Marrow–Derived Progenitor Cells Correlate with Metastatic Disease in Patients with Pediatric Solid Malignancies por Mélissa Taylor, Jochen Rößler, Birgit Geoerger, Agnès Laplanche, Olivier Hartmann, Gilles Vassal, Françoise Farace

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    The selective VEGFR1‐3 inhibitor axitinib (AG‐013736) shows antitumor activity in human neuroblastoma xenografts

    The selective VEGFR1‐3 inhibitor axitinib (AG‐013736) shows antitumor activity in human neuroblastoma xenografts por Jochen Rößler, Yann Monnet, Françoise Farace, Paule Opolon, Estelle Daudigeos‐Dubus, Abderrahmane Bourredjem, Gilles Vassal, Birgit Geoerger

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Dabrafenib, alone or in combination with trametinib, in <i>BRAF</i> V600–mutated pediatric Langerhans cell histiocytosis

    Dabrafenib, alone or in combination with trametinib, in <i>BRAF</i> V600–mutated pediatric Langerhans cell histiocytosis por James A. Whitlock, Birgit Geoerger, Ira J. Dunkel, Sy Ha, Jeea Choi, Lisa Osterloh, Mark W. Russo, Darren Hargrave

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors

    Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors por Estelle Daudigeos‐Dubus, Ludivine Le Dret, Olivia Bawa, Paule Opolon, Albane Vievard, Irène Villa, Jacques Bosq, Gilles Vassal, Birgit Geoerger

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

    Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma por Birgit Geoerger, Mark W. Kieran, Stephan A. Grupp, Danuta Perek, Jill S. Clancy, Mizue Krygowski, Revathi Ananthakrishnan, Joseph Boni, Anna Berkenblit, Sheri L. Spunt

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts

    Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts por Birgit Geoerger, Jacques Grill, Paule Opolon, Jackie Morizet, Geneviève Aubert, Yann Lécluse, Victor W. van Beusechem, Winald R. Gerritsen, David H. Kirn, Gilles Vassal

    Publicado 2003
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric <i>BRAF</i> V600–Mutant Low-Grade Glioma

    Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric <i>BRAF</i> V600–Mutant Low-Grade Glioma por Éric Bouffet, Birgit Geoerger, Christopher L. Moertel, James A. Whitlock, Isabelle Aerts, Darren Hargrave, Lisa Osterloh, Eugene Tan, Jeea Choi, Mark W. Russo, Elizabeth Fox

    Publicado 2022
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models

    Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models por Estelle Daudigeos‐Dubus, Ludivine Le Dret, Claudia Lanvers‐Kaminsky, Olivia Bawa, Paule Opolon, Albane Vievard, Irène Villa, Mélanie Pagès, Jacques Bosq, Gilles Vassal, Dieter Zopf, Birgit Geoerger

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma

    Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma por Nathalène Truffaux, Cathy Philippe, Janna Paulsson, Felipe Andreiuolo, Léa Guerrini‐Rousseau, Gaétan Cornilleau, Ludivine Le Dret, Catherine Richon, Ludovic Lacroix, Stéphanie Puget, Birgit Geoerger, Gilles Vassal, Arne Östman, Jacques Grill

    Publicado 2014
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma

    Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma por Heribert Juergens, Najat C. Daw, Birgit Geoerger, Stefano Ferrari, Milena Villarroel, Isabelle Aerts, Jeremy Whelan, Uta Dirksen, Mary L. Hixon, Donghua Yin, Tao Wang, Stephanie Green, Luisa Paccagnella, Antonio Gualberto

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Targeting the EWSR1-FLI1 Oncogene-Induced Protein Kinase PKC-β Abolishes Ewing Sarcoma Growth

    Targeting the EWSR1-FLI1 Oncogene-Induced Protein Kinase PKC-β Abolishes Ewing Sarcoma Growth por Didier Surdez, Magdalena Benetkiewicz, Virginie Perrin, Zhi‐Yan Han, Gaëlle Pierron, Stelly Ballet, François Lamoureux, Françoise Rédiní, Anne‐Valérie Decouvelaere, Estelle Daudigeos‐Dubus, Birgit Geoerger, Gonzague de Pinieux, Olivier Delattre, Franck Tirode

    Publicado 2012
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’

    The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangemen... por Patrick Schöffski, Agnieszka Woźniak, Michael Leahy, Steinar Aamdal, Piotr Rutkowski, Sebastian Bauer, Stephan Richter, Viktor Grünwald, Maria Dębiec‐Rychter, Raf Sciot, Birgit Geoerger, Sandrine Marréaud, Sandra Collette, Axelle Nzokirantevye, Sandra J. Strauss

    Publicado 2018
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Outcome of children with relapsed or refractory neuroblastoma: A meta‐analysis of ITCC/SIOPEN European phase II clinical trials

    Outcome of children with relapsed or refractory neuroblastoma: A meta‐analysis of ITCC/SIOPEN European phase II clinical trials por Lucas Moreno, Hervé Rubie, Amalia Varo, Marie‐Cécile Le Deley, Loredana Amoroso, Aurélie Chevance, Alberto Garaventa, Marion Gambart, Francisco Bautista, Dominique Valteau‐Couanet, Birgit Geoerger, Gilles Vassal, Xavier Paolettí, Andrew D.J. Pearson

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  18. 18
    Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study

    Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study por Michela Casanova, Francisco Bautista, Quentin Campbell-Hewson, Guy Makin, Lynley V. Marshall, Arnauld Verschuur, Adela Cañete, Nadège Corradini, Bart A. Ploeger, Barbara J. Brennan, Udo Mueller, Hong Zebger‐Gong, John W. Chung, Birgit Geoerger

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma – A report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE)

    Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile an... por Véronique Minard‐Colin, Jean-Laurent Ichante, Laurent Nguyen, Angélo Paci, Daniel Orbach, Christophe Bergeron, Anne Sophie Defachelles, Nicolás André, Nadège Corradini, Claudine Schmitt, Marie‐Dominique Tabone, Pascale Blouin, Nicolas Sirvent, G. Goma, Birgit Geoerger, Odile Oberlin

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

    Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study por Darren Hargrave, Éric Bouffet, Uri Tabori, Alberto Broniscer, Kenneth J. Cohen, Jordan R. Hansford, Birgit Geoerger, Pooja Hingorani, Ira J. Dunkel, Mark W. Russo, Lillian Tseng, Kohinoor Dasgupta, Eduard Gasal, James A. Whitlock, Mark W. Kieran

    Publicado 2019
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: